Chmp gives nod for Sanofi’s Cenrifki for multiple sclerosis BioWorld 21:26 Fri, 24 Apr Article paywall
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Sanofi (Press Release) 19:45 Fri, 24 Apr
Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval FiercePharma 16:39 Fri, 24 Apr
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings Pharmaceutical Technology 15:57 Fri, 24 Apr
Sanofi pounces on Friday window with €2.3bn triple trancher Global Capital 15:02 Fri, 24 Apr Article paywall
MSD, Sanofi boost dividends from Korea as pharma units keep cash flowing to headquarters Korea Biomedical Review 09:24 Fri, 24 Apr
Gujarat Themis Biosyn zooms 14% on acquiring Sanofi's TB drug portfolio The Business Standard 08:30 Fri, 24 Apr
Dupi whoopie: Sanofi/Regeneron cheered for sales, new approval BioWorld 21:31 Thu, 23 Apr Article paywall
With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivity FiercePharma 18:47 Thu, 23 Apr
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria WebWire 16:14 Thu, 23 Apr
Ousted Hudson Hailed As Sanofi Enters New Era With CEO Garijo Scrip Pharma Intelligence 12:52 Thu, 23 Apr
Sanofi receives FDA approval for Tzield in paediatric diabetes Pharmaceutical Business Review 11:05 Thu, 23 Apr
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Sanofi (Press Release) 06:38 Thu, 23 Apr
Sanofi: FDA Approves Dupixent For Young Children With Uncontrolled Chronic Pontaneous Urticaria RTT News 05:48 Thu, 23 Apr
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Sanofi (Press Release) 22:41 Wed, 22 Apr
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children WebWire 16:24 Wed, 22 Apr
Regulatory tracker: FDA delays decision on Sanofi's subcutaneous Sarclisa FiercePharma 16:09 Wed, 22 Apr
Sanofi's Tzield Wins Expanded FDA Approval For Young Children At Risk Of Type 1 Diabetes RTT News 10:17 Wed, 22 Apr
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Sanofi (Press Release) 06:13 Wed, 22 Apr
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study Sanofi (Press Release) 06:13 Wed, 22 Apr
Sanofi defends Dupixent’s lead in Korea eczema market with long-term data Korea Biomedical Review 08:40 Tue, 21 Apr
Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike FiercePharma 15:59 Mon, 20 Apr
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Sanofi (Press Release) 11:06 Sat, 18 Apr
Dividend stocks next week: Cie Automotive, Sanofi, Schaeffler to go ex-date The Business Standard 08:30 Fri, 17 Apr
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria WebWire 01:46 Tue, 14 Apr
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP Sanofi (Press Release) 06:12 Mon, 13 Apr
ADEL Raises $33M In Pre-IPO Round After Major Sanofi Deal Scrip Pharma Intelligence 01:36 Mon, 13 Apr
Sanofi’s bispecific scores in respiratory diseases but fails in eczema Clinical Trials Arena 09:41 Wed, 08 Apr
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP WebWire 16:52 Tue, 07 Apr
